(Total Views: 540)
Posted On: 05/27/2021 11:30:17 PM
Post# of 153886
The ultimate goal at this point is to show to the world that Leronlimab is successful in one Covid trial. Optimizing dosage could be done after you have the market. We should use 700mg for Moderate trial in Brazil.
I can see a pattern that CYDY try to do many things in one trial. For example, why mix mild and moderate in CD10, but you don't control the ratio of enrollment mild and moderate. What if there were only 2 moderate patients enrolled in total, does that help your study for moderate patients?
Same thing for CD12, allowed server/critical but didn't control the ratio of server/critical population, so having too few critical patients in the critical subgroup is the end result.
Another thing is that why didn't they predefined subgroup endpoints as secondary endpoints? Since we tried to cover a diverse patients, shouldn't we expect the efficacy of the drug is different on different patients and make sure the distribution of patients are equal in treatment and placebo arms?
I can see a pattern that CYDY try to do many things in one trial. For example, why mix mild and moderate in CD10, but you don't control the ratio of enrollment mild and moderate. What if there were only 2 moderate patients enrolled in total, does that help your study for moderate patients?
Same thing for CD12, allowed server/critical but didn't control the ratio of server/critical population, so having too few critical patients in the critical subgroup is the end result.
Another thing is that why didn't they predefined subgroup endpoints as secondary endpoints? Since we tried to cover a diverse patients, shouldn't we expect the efficacy of the drug is different on different patients and make sure the distribution of patients are equal in treatment and placebo arms?
(3)
(0)
